Experimental immune cell therapy for a specific type of brain cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a personalized immune cell treatment for a glioblastoma brain tumor that has a specific marker called EGFRvIII. The cells are made in a lab and given by infusion, and the study aims to see if they can safely target and attack the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a glioblastoma brain tumor with a specific marker called EGFRvIII (tested by a lab).
- You are able to do most daily activities (Karnofsky score 70 or higher).
- Your heart, lungs, liver, and kidneys are working well enough to participate.
- You have received standard radiation therapy for your brain tumor.
- You have not had certain other cancer treatments or an EGFR-targeting therapy.
- You are willing to give consent for the study procedures, including a blood collection for making the cells.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests BRiTE, a custom immune “match” therapy designed to attack glioblastoma cells that have a specific EGFRvIII change. It’s for adults with newly diagnosed or recurring grade 4 glioblastoma, aiming to see safety and whether the treatment can shrink or control tumors.
This trial tests a special immune cell treatment (CAR-T cells) that targets two proteins found on glioblastoma cells. It is for patients whose tumor has come back or not responded to standard treatments.
This trial tests a new treatment using your own immune cells that are genetically modified to find and attack brain tumor cells. It is for people with a type of brain cancer that has come back after standard therapy.
This trial tests whether adding a personalized vaccine made from your own immune cells and tumor can help standard chemotherapy and radiation work better against glioblastoma. It is for patients who have already had surgery and are starting or have just finished their first round of chemoradiation.
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) to treat glioblastoma that has come back after standard treatment. The vaccine is designed to help your immune system recognize and attack your tumor.
This trial tests a new approach using immune cells called cytokine-induced killer cells to treat glioblastoma. It aims to find the best way to prepare these cells to fight the tumor.
Hear when a new EGFR Gene Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.